Skip to main content
NCBI home page
British Journal of Experimental Pathology logoLink to British Journal of Experimental Pathology
. 1988 Feb;69(1):69–80.

Type 2 pneumocyte responses to cyclophosphamide-induced pulmonary injury: functional and morphological correlation.

R K Kumar 1, J Y Truscott 1, G C Rhodes 1, A W Lykke 1
PMCID: PMC2013190  PMID: 3348961

Abstract

We investigated the correlation between the functional and morphological responses of type 2 pneumocytes to experimentally induced subacute lung damage. BALB/c mice were injected with a single dose of 300 mg/kg of cyclophosphamide intraperitoneally to induce alveolar epithelial injury. Groups of six cyclophosphamide-treated animals and three untreated controls were killed at 3 days and 1, 2, 3, 4, 6, 8 and 12 weeks after drug treatment. The net secretory response of type 2 pneumocytes to injury was assessed by an enzyme immunoassay for the surfactant-associated protein alveolyn in bronchoalveolar lavage fluid and the morphological responses of the alveolar epithelial cells were evaluated by light and electron microscopy. Early type I pneumocyte injury occurred without significant endothelial damage and was accompanied by intra-alveolar fibrinous exudation. This was followed by focal hypertrophy and apparent hyperplasia of type 2 pneumocytes, together with the progressive accumulation of large foamy intra-alveolar macrophages and focal pleural fibrosis. In a minority of animals these lesions progressed to intra-alveolar fibrosis with marked epithelial hyperplasia. The type 2 pneumocyte response was initially paralleled by an increase in the concentration of alveolyn in bronchoalveolar lavage fluid, which was significantly greater than control values at 1 and 2 weeks (P less than 0.005) as well as at 3 and 4 weeks (P less than 0.05) after injury induced by cyclophosphamide, but thereafter fell to control levels. This study demonstrates that cyclophosphamide induces morphological alterations of type 2 pneumocytes and altered secretory activity of these cells manifested as an increased net secretion of a surfactant-associated protein.

Full text

PDF
69

Images in this article

76Fig. 5
on p.76
76Fig. 6
on p.76
72Fig. 1
on p.72
73Fig. 2
on p.73
74Fig. 3
on p.74
75Fig. 4
on p.75
77Fig. 7
on p.77

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aso Y., Yoneda K., Kikkawa Y. Morphologic and biochemical study of pulmonary changes induced by bleomycin in mice. Lab Invest. 1976 Dec;35(6):558–568. [PubMed] [Google Scholar]
  2. Beckman D. L., Weiss H. S. Hyperoxia compared to surfactant washout on pulmonary compliance in rats. J Appl Physiol. 1969 Jun;26(6):700–709. doi: 10.1152/jappl.1969.26.6.700. [DOI] [PubMed] [Google Scholar]
  3. Chrétien J., Basset F., Jaubert F., Soler P., Danel C. Cellular biology and pathology of type II pneumocytes. Int Arch Allergy Appl Immunol. 1985;76 (Suppl 1):49–61. doi: 10.1159/000233735. [DOI] [PubMed] [Google Scholar]
  4. Cooper J. A., Jr, White D. A., Matthay R. A. Drug-induced pulmonary disease. Part 1: Cytotoxic drugs. Am Rev Respir Dis. 1986 Feb;133(2):321–340. doi: 10.1164/arrd.1986.133.2.321. [DOI] [PubMed] [Google Scholar]
  5. Depledge M. H. Dose-independence of early, cyclophosphamide-induced lung damage in mice. Jpn J Exp Med. 1984 Dec;54(6):235–239. [PubMed] [Google Scholar]
  6. Gabor S., Zugravu E., Kováts A., Böhm B., Andrasoni D. Effects of quartz on lung surfactant. Environ Res. 1978 Jul;16(1-3):443–448. doi: 10.1016/0013-9351(78)90177-9. [DOI] [PubMed] [Google Scholar]
  7. Kikkawa Y., Smith F. Cellular and biochemical aspects of pulmonary surfactant in health and disease. Lab Invest. 1983 Aug;49(2):122–139. [PubMed] [Google Scholar]
  8. Kumar R. K., Lykke A. W., Truscott J. Y., Watkins S. G., Smith G. J. Immunohistochemical identification of type 2 pneumocytes by an antibody to a lamellar body-enriched fraction of lung homogenate. Lung. 1985;163(4):243–253. doi: 10.1007/BF02713824. [DOI] [PubMed] [Google Scholar]
  9. Kumar R. K., Smith G. J., Truscott J. Y., Hristoforidis C. P., Lykke A. W. Characterization of an alveolyn-like protein associated with mouse type 2 pneumocytes using immunochemical methods. Biochem Biophys Res Commun. 1986 Sep 30;139(3):1135–1141. [PubMed] [Google Scholar]
  10. Le Mesurier S. M., Lykke A. W., Stewart B. W. Reduced yield of pulmonary surfactant: patterns of response following administration of chemicals to rats by inhalation. Toxicol Lett. 1980 Jan;5(1):89–93. doi: 10.1016/0378-4274(80)90153-8. [DOI] [PubMed] [Google Scholar]
  11. Lemaire I., Beaudoin H., Massé S., Grondin C. Alveolar macrophage stimulation of lung fibroblast growth in asbestos-induced pulmonary fibrosis. Am J Pathol. 1986 Feb;122(2):205–211. [PMC free article] [PubMed] [Google Scholar]
  12. Lynn W. S. Alveolyn--structure and source: a review. Exp Lung Res. 1984;6(3-4):191–196. doi: 10.3109/01902148409109247. [DOI] [PubMed] [Google Scholar]
  13. Morse C. C., Sigler C., Lock S., Hakkinen P. J., Haschek W. M., Witschi H. P. Pulmonary toxicity of cyclophosphamide: a 1-year study. Exp Mol Pathol. 1985 Apr;42(2):251–260. doi: 10.1016/0014-4800(85)90031-0. [DOI] [PubMed] [Google Scholar]
  14. Stewart B. W., Le Mesurier S. M., Lykke A. W. Correlation of biochemical and morphological changes induced by chemical injury to the lung. Chem Biol Interact. 1979 Aug;26(3):321–338. doi: 10.1016/0009-2797(79)90035-8. [DOI] [PubMed] [Google Scholar]
  15. Weissman I. L. Nursing the thymus. Lab Invest. 1986 Jul;55(1):1–4. [PubMed] [Google Scholar]

Articles from British journal of experimental pathology are provided here courtesy of Wiley

RESOURCES